Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
graft vs. host disease
Pharma
BMS's Orencia wins FDA nod for prevention of GVHD
The FDA has endorsed BMS's Orencia for the prevention of acute graft-versus-host disease (GVHD) in combination with certain immunosuppressants.
Kevin Dunleavy
Dec 15, 2021 3:25pm
Incyte snags 2nd JAK nod in 2 days—this time for Jakafi
Sep 23, 2021 10:20am
Acquisitive Sanofi buys GVHD drug via $1.9B takeover of Kadmon
Sep 8, 2021 8:16am
BMS' Orencia snagged priority review in transplant rejection
Aug 23, 2021 11:02am
Kadmon gears up for its first-ever commercial drug launch
Jul 19, 2021 3:49pm
Kadmon's Rezurock scores surprise FDA nod
Jul 16, 2021 3:20pm
